Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517906 | 0.91 | FAAH (0.57) | FAAHEPHX1ALDH1A1RAB9AKDM4E | |
| SCHEMBL5520154 | 0.84 | RAB9A (0.45) | FAAHALDH1A1RAB9A | |
| SCHEMBL14470498 | 0.80 | RAB9A (0.47) | ALDH1A1RAB9AKDM4E | |
| SCHEMBL5523279 | 0.78 | RAB9A (0.64) | EPHX1ALDH1A1RAB9AKDM4E | |
| SCHEMBL4970032 | 0.77 | FAAH (0.57) | FAAHEPHX1ALDH1A1RAB9A | |
| SCHEMBL9202106 | 0.76 | RAB9A (0.59) | RAB9AKDM4E | |
| SCHEMBL6629605 | 0.76 | RAB9A (0.54) | ALDH1A1RAB9AKDM4E | |
| SCHEMBL5524316 | 0.75 | MMP13 (0.44) | FAAH | |
| SCHEMBL4968604 | 0.74 | MAOB (0.59) | FAAHEPHX1ALDH1A1RAB9A | |
| SCHEMBL1690730 | 0.74 | RAB9A (0.71) | FAAHEPHX1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1969051-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2008-09-17 | — | — | EP | disclosed |
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030752-A2 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007079180-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | FAAH, FAAH2, FADS1 | FAAH 1/4885EPHX1 43/4885ALDH1A1 253/4885 |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | FAAH 1/4885EPHX1 84/4885ALDH1A1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.